NEWSLETTER

• As the leading clinically-driven pharmacy care company, EmpiRx Health puts the pharmacist at the center of our PBM service model. This unique approach drives our evidence-based, clinically-appropriate therapy recommendations that ensure the health and wellbeing of members while helping our clients to substantially reduce costs.
• Does your PBM have a state-of-the-art population health engine that powers clinically-driven pharmacy care decisions? EmpiRx Health’s proprietary population health engine helps to optimize patient health and wellbeing while substantially reducing drug costs.
• EmpiRx Health’s industry-leading biosimilars substitution/utilization rate – 15% vs ~2% with other PBM models.​​​​​​ 19% are LOW list price biosimilars.

This month EmpiRx Health proudly announced the launch of Clinically™, our breakthrough pharmacy care platform! As the first clinically-driven PBM technology platform, Clinically puts clients and members first by enabling effective pharmacist/physician collaboration and driving transparency, pricing clarity, flexibility, and innovation. Click here for more information!

EmpiRx Health’s CEO, Danny Sanchez, is featured in an interview by Drug Store News, a leading trade publication covering the retail pharmacy industry. In the video interview, Danny shares his thoughts on the future of PBMs and why a clinically-driven pharmacy care model is the best choice for plan sponsors looking to ensure the health and wellbeing of their members while substantially reducing prescription drug costs. A huge thank you to Drug Store News and John Kenlon for featuring us in such a fantastic interview! Watch now!

Population Health Management Engine Identified: 60-year-old female with Osteoporosis. 

Original Rx: Forteo 20mcg daily injection

Clinical Pharmacist reviewed the request for Forteo injection and suggested a first line oral medication, due to the patient’s fear of needles and Forteo requiring daily injections.

New Therapy: Alendronate 70mg tablet by mouth taken once weekly

$41,608 Annual Plan Savings achieved.

Population Health Management Engine Identified: 63-year-old male with Lung adenocarcinoma

Original Rx: Tagrisso 40mg twice a day

After detailed review of clinical chart notes, our Clinical pharmacist identified that the prescribed dosage could exacerbate the patient’s existing cardiomyopathy, which could be life-threatening.

New Therapy: Tagrisso 40 mg once a day

$15,695 Annual Plan Savings achieved.